Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 3:49 PM
Ignite Modification Date: 2025-12-25 @ 1:56 PM
NCT ID: NCT04564092
Description: None
Frequency Threshold: 0
Time Frame: Baseline up to 2 weeks after IMP administration (i.e., up to 16 days)
Study: NCT04564092
Study Brief: A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
DaTSCAN™ Ioflupane (123I) Injection Participants received a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV at Day 1; followed by planar whole-body imaging at 10 minutes, 1 hour, 2 hours, 4 hours, 5 hours, 24 hours, and 48 hours after administration. Brain SPECT imaging was performed at 3 and 6 hours after administration. 0 None 0 8 7 8 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Aspartate aminotransferase increased SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View
Protein urine present SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View
Urinary occult blood positive SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View
White blood cell count decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View
Hypoglycaemia SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA Version 24.1 View
Paraesthesia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA Version 24.1 View
Thyroiditis chronic SYSTEMATIC_ASSESSMENT Endocrine disorders MedDRA Version 24.1 View
Neutrophil count decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View
Red blood cells urine positive SYSTEMATIC_ASSESSMENT Investigations MedDRA Version 24.1 View